[Effect of diagnostic X-rays on implantable cardiac pacemakers and implantable cardioverter defibrillators, and its management]

Initial testing of pegfilgrastim (Neulasta Onpro) on-body injector in multiple radiological imaging environments

Purpose

An increasing number of implantable or external devices can impact whether patients can receive radiological imaging examinations. This study examines and tests the Neulasta (pegfilgrastim) Onpro on‐body injector in multiple imaging environments.

Methods

The injector was analyzed for four imaging modalities with testing protocols and strategies developed for each modality. In x‐ray and computed tomography (CT), scans with much higher exposure than clinical protocols were performed with the device attached to an anthropomorphic phantom. The device was monitored until the completion of drug delivery. For magnetic resonance imaging (MRI), the device was assessed using a hand‐held magnet and underwent the magnetically induced displacement testing in a 1.5T clinical MRI scanner room. For ultrasound, magnetic field changes were measured around an ultrasound scanner system with three transducers.

Results

For x‐ray and CT no sign of device error was identified during or after the high radiation exposure scans. Drug delivery was completed at expected timing with expected volume. For MRI the device showed significant attractive force towards the hand‐held magnet and a 50‐degree deflection angle at 50 cm from the opening of the scanner bore. No further assessment from the gradient or radiofrequency field was deemed necessary. For ultrasound the maximum magnetic field change from baseline was measured to be +11.7 μT in comparison to +74.2 μT at 4 inches from a working microwave.

Conclusions

No device performance issue was identified under the extreme test conditions in x‐ray or CT. The device was found to be MR Unsafe. Magnetic field changes around an ultrasound system met the limitation set by manufacture. Patient ultrasound scanning is considered safe as long as the transducers do not inadvertently loosen the device.

[Partial electrical reset of CT irradiation on implantable cardiac devices: relationship between reset and tube voltage, tube current, and rotation time]

The aim of this study was to investigate the relationship between partial electrical reset (PER) and CT scan parameters (tube voltage, tube current, rotation time, and product of tube current and rotation time in mAs). A cardiac resynchronization therapy pacemaker (Insync 8040, Medtronic Inc., Tokyo) and 320 area detector CT scanner (Aquilion ONE, Toshiba medical systems, Otawara, Japan) with volume scan were used. The pacemaker was put in DDD mode. The PERs were interpreted using both the programmer's wave forms and error messages. The exposure was repeated 5 times per CT setting. The pacemaker was placed on the anterior wall and upper side of a chest phantom. Each CT scan was performed using the following parameters: tube voltage of 80, 100, 120, and 135 kV; tube current of 50-550 mA; and rotation time of 0.35-1.5 s. PERs were observed at 100, 120, and 135 kV, and more PERs were observed as the tube voltage increased. The PER tube current decreased as the rotation time was increased. In contrast, the PER tube current and rotation time product (mAs) increased as the rotation time was increased. More specifically, the radiation dose rate was the affected factor of the PERs. To avoid PER of pacemakers, CT scan parameters with lower radiation dose rates (low rather than high tube current and rotational time) is recommended. In conclusion, our results will help with CT scans of patients who have implantable cardiac devices (included pacemakers and cardioverter defibrillators).

Computed Tomography Scan and ICD Interaction

Although it has been considered a safe procedure, computed tomography scanning uses high doses of radiation and can cause malfunctioning in those patients with ICD when the radiation is directly incident on the device. We present a case of ventricular oversensing during a thoracic computed tomography.